What is the difference between an ARB (irbesartan) and an ACE inhibitor (lisinopril)?

Both ARBs and ACE inhibitors lower blood pressure by reducing angiotensin II activity, but through different mechanisms. ACE inhibitors prevent formation of angiotensin II; ARBs block its receptor. Both provide kidney protection in diabetic nephropathy. The key practical difference: ACE inhibitors cause a dry cough in up to 15-20% of patients (due to bradykinin accumulation); ARBs almost never cause cough. Switching from ACE inhibitor to ARB due to cough is very effective.

Why does irbesartan raise potassium?

By reducing angiotensin II activity, irbesartan reduces the stimulation of aldosterone, a hormone that causes potassium excretion in the kidney. Less aldosterone means less potassium excretion, leading to potassium retention. For most patients, this is modest and beneficial. In patients with kidney disease, diabetes, or those taking potassium-sparing diuretics, monitoring is important.

Is irbesartan safe to take during pregnancy?

No. ARBs (and ACE inhibitors) are contraindicated in pregnancy. They can cause serious fetal harm and death, particularly affecting fetal kidney development. Stop irbesartan immediately if you become pregnant and contact your OB/GYN. Use effective contraception if you are of childbearing potential.

How long will I need to take irbesartan?

Irbesartan is typically a lifelong medication for hypertension or diabetic nephropathy. Stopping causes blood pressure to return to previous levels and eliminates kidney protection. If your blood pressure is well controlled and you wish to try stopping, this should be done only with your prescriber's guidance, combined with lifestyle modifications.

What to Expect When Starting Irbesartan

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Irbesartan is an angiotensin receptor blocker (ARB) used to treat hypertension and diabetic nephropathy (kidney disease in type 2 diabetes). It works by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict. ARBs are well-tolerated with a side effect profile similar to placebo in many patients, and unlike ACE inhibitors, they do not cause a dry cough. Blood pressure lowering begins within hours of the first dose.

Week-by-week timeline

Day 1-3

First Doses and Blood Pressure Response

Irbesartan begins lowering blood pressure within 1-2 hours of the first dose, with peak effect at 3-6 hours. Initial dizziness or lightheadedness when standing (orthostatic hypotension) is common, especially if also taking diuretics or other antihypertensives. Rise slowly from sitting or lying positions during the first week.

Week 1

Adjustment Period

Dizziness typically improves over the first week. Check blood pressure at home if you have a monitor. Contact your prescriber if blood pressure is below 90/60 mmHg or you feel faint. Potassium levels should be monitored — ARBs can raise potassium, particularly in patients with kidney disease.

Week 2-4

Blood Pressure Stabilization

Full antihypertensive effect is typically achieved within 1-2 weeks at a stable dose. For diabetic nephropathy, irbesartan reduces protein in the urine (proteinuria), which is tracked as a marker of kidney protection. Kidney function and potassium are typically checked 1-2 weeks after starting.

Month 1

Follow-Up and Lab Monitoring

A follow-up visit to check blood pressure, kidney function (creatinine, eGFR), and potassium is standard. Some increase in creatinine is expected and acceptable (up to 25-30% above baseline) — this reflects the drug's mechanism. A larger rise or rise combined with declining urine output should be investigated.

Month 2-3

Long-Term Kidney and BP Protection

Irbesartan (and other ARBs) provide kidney protective effects beyond blood pressure lowering in diabetic nephropathy. The IDNT trial demonstrated significant slowing of kidney disease progression. Long-term therapy continues with periodic monitoring of blood pressure, kidney function, and potassium.

When to call your doctor

Contact your healthcare provider if you experience:

Severe dizziness or fainting (excessive blood pressure lowering)
Significant swelling of face, lips, tongue, or throat (angioedema — rare with ARBs but possible; seek emergency care immediately)
Elevated potassium symptoms: muscle weakness, irregular heartbeat, tingling (hyperkalemia)
Significant decrease in urine output or rapid weight gain (worsening kidney function)
Severe abdominal pain (rare)
Signs of allergic reaction: rash, difficulty breathing

Tips for getting started

Monitor blood pressure at home if you have a monitor and share readings with your prescriber. Potassium-rich foods (bananas, oranges, potatoes, spinach) can further raise potassium when taking irbesartan — moderation is reasonable without being extreme. Avoid NSAIDs (ibuprofen, naproxen) — they reduce ARB effectiveness and can worsen kidney function. Avoid potassium supplements and salt substitutes containing potassium unless directed. Do not use with ACE inhibitors or aliskiren — this combination dramatically increases hyperkalemia and kidney toxicity risk. Stay well hydrated.

Frequently asked questions

More about Irbesartan

Irbesartan drug guideSide effects, dosage, interactions, and more Losartan vs IrbesartanCompare these medications Irbesartan vs LosartanCompare these medications Lisinopril & IrbesartanInteraction details Hydrochlorothiazide & IrbesartanInteraction details

References

[Regulatory] FDA Label: Avapro (irbesartan) Tablets https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020757s033lbl.pdf Accessed 2026-03-01.
[Regulatory] NIH MedlinePlus: Irbesartan https://medlineplus.gov/druginfo/meds/a698009.html Accessed 2026-03-01.
[Clinical] IDNT Trial: Irbesartan and Diabetic Nephropathy https://www.nejm.org/doi/10.1056/NEJMoa011303 Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: March 1, 2026